{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:58:46Z","timestamp":1789786726494,"version":"4.0.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T00:00:00Z","timestamp":1535155200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Syst Rev"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13643-018-0779-5","type":"journal-article","created":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T05:07:20Z","timestamp":1535173640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Blood pressure reduction and clinical outcomes with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: protocol for a systematic review and meta-regression analysis"],"prefix":"10.1186","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4102-5418","authenticated-orcid":false,"given":"Jonathan A.","family":"Batty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlous","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin H.","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alistair S.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,25]]},"reference":[{"issue":"4 Pt 2","key":"779_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2105\/AJPH.47.4_Pt_2.4","volume":"47","author":"TR Dawber","year":"1957","unstructured":"Dawber TR, Moore FE, Mann GV. Coronary heart disease in the Framingham study. Am J Public Health Nations Health. 1957;47(4 Pt 2):4\u201324.","journal-title":"Am J Public Health Nations Health"},{"key":"779_CR2","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.2105\/AJPH.55.9.1355","volume":"55","author":"WB Kannel","year":"1965","unstructured":"Kannel WB, Dawber TR, Cohen ME, McNamara PM. Vascular disease of the brain -- epidemiologic aspects: the Framingham study. Am J Public Health Nations Health. 1965;55:1355\u201366.","journal-title":"Am J Public Health Nations Health"},{"issue":"20","key":"779_CR3","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.1996.03530440037034","volume":"275","author":"D Levy","year":"1996","unstructured":"Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557\u201362.","journal-title":"JAMA"},{"issue":"9199","key":"779_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S0140-6736(99)07051-8","volume":"355","author":"S Port","year":"2000","unstructured":"Port S, Demer L, Jennrich R, Walter D, Garfinkel A. Systolic blood pressure and mortality. Lancet (London, England). 2000;355(9199):175\u201380.","journal-title":"Lancet (London, England)"},{"issue":"10022","key":"779_CR5","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet (London, England). 2016;387(10022):957\u201367.","journal-title":"Lancet (London, England)"},{"issue":"30","key":"779_CR6","doi-asserted-by":"publisher","first-page":"e4071","DOI":"10.1097\/MD.0000000000004071","volume":"95","author":"MA Paz","year":"2016","unstructured":"Paz MA, de-La -Sierra A, S\u00e1ez M, Barcel\u00f3 MA, Rodr\u00edguez JJ, Castro S, et al. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine. 2016;95(30):e4071.","journal-title":"Medicine"},{"issue":"16","key":"779_CR7","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1093\/eurheartj\/ehs075","volume":"33","author":"LC van Vark","year":"2012","unstructured":"van Vark LC, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad J-J, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin\u2013angiotensin\u2013aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33(16):2088\u201397.","journal-title":"Eur Heart J"},{"issue":"22","key":"779_CR8","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/CIRCULATIONAHA.117.026112","volume":"135","author":"MH Strauss","year":"2017","unstructured":"Strauss MH, Hall AS. Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI paradox. Circulation. 2017;135(22):2088\u201390.","journal-title":"Circulation"},{"issue":"22","key":"779_CR9","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1161\/CIRCULATIONAHA.116.025950","volume":"135","author":"FH Messerli","year":"2017","unstructured":"Messerli FH, Bangalore S. Angiotensin receptor blockers reduce cardiovascular events, including the risk of myocardial infarction. Circulation. 2017;135(22):2085\u20137.","journal-title":"Circulation"},{"issue":"1","key":"779_CR10","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.mayocp.2015.10.019","volume":"91","author":"S Bangalore","year":"2016","unstructured":"Bangalore S, Fakheri R, Toklu B, Ogedegbe G, Weintraub H, Messerli FH. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients without heart failure? Insights from 254,301 patients from randomized trials. Mayo Clin Proc. 2016;91(1):51\u201360.","journal-title":"Mayo Clin Proc"},{"issue":"9426","key":"779_CR11","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet (London, England). 2004;363(9426):2022\u201331.","journal-title":"Lancet (London, England)"},{"issue":"1","key":"779_CR12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/sj.jhh.1001931","volume":"20","author":"BM Cheung","year":"2006","unstructured":"Cheung BM, Cheung GT, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large outcome trials of angiotensin receptor blockers in hypertension. J Hum Hypertens. 2006;20(1):37\u201343.","journal-title":"J Hum Hypertens"},{"issue":"8","key":"779_CR13","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1161\/CIRCULATIONAHA.105.594986","volume":"114","author":"MH Strauss","year":"2006","unstructured":"Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction: unraveling the ARB-MI paradox. Circulation. 2006;114(8):838\u201354.","journal-title":"Circulation"},{"issue":"S5","key":"779_CR14","doi-asserted-by":"publisher","first-page":"134S","DOI":"10.1016\/j.amjhyper.2005.05.005","volume":"18","author":"BI Levy","year":"2005","unstructured":"Levy BI. How to explain the differences between renin angiotensin system modulators*. Am J Hypertens. 2005;18(S5):134S\u201341S.","journal-title":"Am J Hypertens"},{"issue":"6","key":"779_CR15","doi-asserted-by":"publisher","first-page":"R1729","DOI":"10.1152\/ajpregu.00385.2005","volume":"289","author":"C Warnecke","year":"2005","unstructured":"Warnecke C, Mugrauer P, S\u00fcrder D, Erdmann J, Schubert C, Regitz-Zagrosek V. Intronic ANG II type 2 receptor gene polymorphism 1675 G\/A modulates receptor protein expression but not mRNA splicing. Am J Physiol Regul Integr Comp Physiol. 2005;289(6):R1729\u2013R35.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"15","key":"779_CR16","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","volume":"358","author":"The ONTARGET Investigators","year":"2008","unstructured":"The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547\u201359.","journal-title":"N Engl J Med"},{"issue":"1","key":"779_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews. 2015;4(1):1.","journal-title":"Systematic Reviews"},{"issue":"7","key":"779_CR18","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.","journal-title":"PLoS Med"},{"key":"779_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/2046-4053-1-2","volume":"1","author":"A Booth","year":"2012","unstructured":"Booth A, Clarke M, Dooley G, Ghersi D, Moher D, Petticrew M, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Systematic Reviews. 2012;1:2.","journal-title":"Systematic Reviews"},{"issue":"2","key":"779_CR20","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3109\/08037059209077502","volume":"1","author":"L Hansson","year":"1992","unstructured":"Hansson L, Hedner T, Dahlof B. Prospective randomized open blinded end-point (PROBE) study. A novel design for intervention trials. Prospective randomized open blinded end-point. Blood Press. 1992;1(2):113\u20139.","journal-title":"Blood Press"},{"issue":"5","key":"779_CR21","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1097\/HJH.0b013e3280bad9b4","volume":"25","author":"F Turnbull","year":"2007","unstructured":"Turnbull F, Neal B, Pfeffer M, Kostis J, Algert C, Woodward M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens. 2007;25(5):951\u20138.","journal-title":"J Hypertens"},{"key":"779_CR22","doi-asserted-by":"crossref","unstructured":"The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145\u201353.","DOI":"10.1056\/NEJM200001203420301"},{"key":"779_CR23","doi-asserted-by":"crossref","unstructured":"Bangalore S, Fakheri R, Wandel S, Toklu B, Wandel J, Messerli FH. Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ. 2017;356:1\u201310","DOI":"10.1136\/bmj.j4"},{"issue":"6964","key":"779_CR24","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","volume":"309","author":"K Dickersin","year":"1994","unstructured":"Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ: Br Med J. 1994;309(6964):1286\u201391.","journal-title":"BMJ: Br Med J"},{"key":"779_CR25","unstructured":"The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT, Green S, editors: 2008."},{"issue":"1","key":"779_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.","journal-title":"BMC Med Res Methodol"},{"key":"779_CR27","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:1\u20139","DOI":"10.1136\/bmj.d5928"},{"issue":"7650","key":"779_CR28","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924\u20136.","journal-title":"BMJ"},{"issue":"3","key":"779_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177\u201388.","journal-title":"Control Clin Trials"},{"key":"779_CR30","doi-asserted-by":"crossref","unstructured":"Blood Pressure Lowering Trialists' Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ: Br Med J. 2013:347.","DOI":"10.1136\/bmj.f5680"},{"key":"779_CR31","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"8","author":"JF Tierney","year":"2007","unstructured":"Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16.","journal-title":"Trials"},{"issue":"9290","key":"779_CR32","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0140-6736(01)06411-X","volume":"358","author":"JA Staessen","year":"2001","unstructured":"Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet (London, England). 2001;358(9290):1305\u201315.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"779_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1161\/01.HYP.0000174591.42889.a2","volume":"46","author":"P Verdecchia","year":"2005","unstructured":"Verdecchia P, Reboldi G, Angeli F, Gattobigio R, Bentivoglio M, Thijs L, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46(2):386\u201392.","journal-title":"Hypertension"},{"issue":"7059","key":"779_CR34","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/bmj.313.7059.735","volume":"313","author":"SJ Sharp","year":"1996","unstructured":"Sharp SJ, Thompson SG, Altman DG. The relation between treatment benefit and underlying risk in meta-analysis. BMJ. 1996;313(7059):735\u20138.","journal-title":"BMJ"},{"issue":"16","key":"779_CR35","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/sim.4780111605","volume":"11","author":"R Brand","year":"1992","unstructured":"Brand R, Kragt H. Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. Stat Med. 1992;11(16):2077\u201382.","journal-title":"Stat Med"},{"issue":"47","key":"779_CR36","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1093\/eurheartj\/ehu424","volume":"35","author":"BR da Costa","year":"2014","unstructured":"da Costa BR, J\u00fcni P. Systematic reviews and meta-analyses of randomized trials: principles and pitfalls. Eur Heart J. 2014;35(47):3336\u201345.","journal-title":"Eur Heart J"}],"container-title":["Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-018-0779-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13643-018-0779-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13643-018-0779-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T19:07:17Z","timestamp":1566673637000},"score":1,"resource":{"primary":{"URL":"https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/10.1186\/s13643-018-0779-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,25]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1186\/s13643-018-0779-5","relation":{},"ISSN":["2046-4053"],"issn-type":[{"value":"2046-4053","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,25]]},"assertion":[{"value":"14 August 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JAB is a clinical research fellow.MT is a resident in internal medicine.MH is a senior epidemiologist.RF is a professor of cardiology.MHS is an attending cardiologist.ASH is a professor of cardiology.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 information"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MHS has received speaker honoraria from and participated in advisory boards for Servier. ASH has received speaker honoraria from Servier. All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"131"}}